Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tokio Study: Third-line TKI after two prior TKIs in metastatic renal cell carcinoma
2014-001956-52Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib, sunitinib, pazopanib and axitinib in metastatic renal cell carcinoma (mRCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Jun 2014; status: terminated.
02
Drugs
sorafenibsunitinibpazopanibaxitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2014-001956-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001956-52.